ES2152986T3 - Genoterapia de celulas mesoteliales. - Google Patents

Genoterapia de celulas mesoteliales.

Info

Publication number
ES2152986T3
ES2152986T3 ES94920753T ES94920753T ES2152986T3 ES 2152986 T3 ES2152986 T3 ES 2152986T3 ES 94920753 T ES94920753 T ES 94920753T ES 94920753 T ES94920753 T ES 94920753T ES 2152986 T3 ES2152986 T3 ES 2152986T3
Authority
ES
Spain
Prior art keywords
mesotelial
cells
expression system
genotherapy
vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94920753T
Other languages
English (en)
Inventor
Ty Robert Shockley
Robert William Jackman
Janice Ann Nagy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Application granted granted Critical
Publication of ES2152986T3 publication Critical patent/ES2152986T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0688—Cells from the lungs or the respiratory tract
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

METODOS Y COMPOSICIONES FARMACEUTICAS PARA MODIFICAR LAS CELULAS MESOTELIALES DE UN RECIPIENTE MAMIFERO IN SITU. LOS METODOS INCLUYEN LA FORMACION DE UN SISTEMA DE EXPRESION DE CELULA MESOTELIAL IN VIVO O EX VIVO Y LA ADMINISTRACION DEL SISTEMA DE EXPRESION AL RECIPIENTE MAMIFERO (MEDIANTE LAS CAVIDADES CORPORALES NORMALMENTE RECUBIERTAS POR LAS CELULAS MESOTELIALES). EL SISTEMA DE EXPRESION DE CELULA MESOTELIAL ES UTIL PARA EL ENVIO LOCALIZADO Y SISTEMICO DE AGENTES TERAPEUTICOS IN SITU.
ES94920753T 1993-06-18 1994-06-15 Genoterapia de celulas mesoteliales. Expired - Lifetime ES2152986T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/080,474 US5645829A (en) 1993-06-18 1993-06-18 Mesothelial cell gene therapy

Publications (1)

Publication Number Publication Date
ES2152986T3 true ES2152986T3 (es) 2001-02-16

Family

ID=22157605

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94920753T Expired - Lifetime ES2152986T3 (es) 1993-06-18 1994-06-15 Genoterapia de celulas mesoteliales.

Country Status (9)

Country Link
US (2) US5645829A (es)
EP (2) EP1024197A3 (es)
JP (1) JP3466194B2 (es)
AT (1) ATE197719T1 (es)
AU (1) AU688342B2 (es)
CA (1) CA2164424A1 (es)
DE (1) DE69426328T2 (es)
ES (1) ES2152986T3 (es)
WO (1) WO1995000654A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
WO1996006933A1 (en) * 1994-08-26 1996-03-07 Sandoz Ltd. Gene therapy for transplantation and inflammatory or thrombotic conditions
US5704910A (en) * 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
DE69839765D1 (de) 1997-01-27 2008-09-04 Ludwig Inst Cancer Res Lage-1 tumor-assozierte nukleinsäuren
CA2205076A1 (en) 1997-05-14 1998-11-14 Jim Hu Episomal expression cassettes for gene therapy
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
WO1999008533A1 (en) * 1997-08-13 1999-02-25 Yale University Central nervous system axon regeneration
US20080233098A1 (en) * 1997-10-31 2008-09-25 Mckerracher Lisa RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US7169783B2 (en) * 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
EP2006300A3 (en) 1998-12-30 2009-03-11 Beth Israel Deaconess Medical Center, Inc. Characterization of a calcium channel family
US7063959B1 (en) 1998-12-30 2006-06-20 Beth Israel Deaconess Medical Center, Inc. Compositions of the SOC/CRAC calcium channel protein family
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US6696272B1 (en) 1999-06-02 2004-02-24 Hsc Research & Development Limited Partnership Products and methods for gaucher disease therapy
DE60044904D1 (de) 1999-09-03 2010-10-14 Brigham & Womens Hospital Verfahren und zusammensetzungen zur behandlung von entzündungskrankheiten unter verwendung von cadherin-11-modulierenden agenzien
US20020142299A1 (en) * 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
DK1515752T3 (da) 2002-06-19 2009-03-23 Univ Health Network ACE2-aktivering til behandling af hjerte-, lunge- og nyresygdomme og hypertension
SI2325302T1 (sl) 2003-02-11 2016-05-31 Shire Human Genetic Therapies, Inc. Celice, ki soizražajo sulfatazo in c-formilglicin generirajoči encim ter postopki in uporabe le-teh
US7335496B2 (en) * 2003-06-05 2008-02-26 Ajinomoto Co., Inc. Method for producing target substance
US20060052324A1 (en) * 2004-08-05 2006-03-09 Artandi Steven E Methods and compositions for cell activation
DE602005022481D1 (de) * 2004-12-08 2010-09-02 Pervasis Therapeutics Inc Zusammensetzungen und deren verwendung für besseren gefässzugang
JP5174656B2 (ja) 2005-04-21 2013-04-03 マサチューセッツ インスティテュート オブ テクノロジー 同系または非同系の細胞、組織または器官を含む、外因性免疫原および内因性免疫原に対する免疫応答を改変するための材料および方法
US20090035346A1 (en) * 2005-06-21 2009-02-05 Pervasis Therpeutics, Inc. Methods and Compositions for Enhancing Vascular Access
US20100204783A1 (en) * 2005-12-06 2010-08-12 Helen Marie Nugent Methods and compositions for enhancing vascular access
US20090068158A1 (en) * 2005-12-09 2009-03-12 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
US20090074733A1 (en) * 2005-12-09 2009-03-19 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
CA2642848C (en) 2006-03-03 2016-07-12 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-sod1 mediated diseases
CA2668621A1 (en) * 2006-11-07 2008-05-15 Pervasis Therapeutics, Inc. Materials and methods for treating and managing angiogenesis-mediated diseases
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
EP2377952A1 (en) 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Methods for diagnosing and treating astrocytomas
CA2723320C (en) 2007-05-04 2019-06-11 University Health Network Il-12 immunotherapy for cancer
US20100185156A1 (en) * 2007-06-13 2010-07-22 Pervasis Therapeutics, Inc. Methods and Devices for Minimally-Invasive Delivery of Cell-Containing Flowable Compositions
EP2077119A1 (de) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
WO2009114942A1 (en) 2008-03-20 2009-09-24 University Health Network Thymidylate kinase fusions and uses thereof
EP2113261B1 (en) * 2008-04-29 2013-11-06 Proxy Biomedical Limited A Tissue Repair Implant
WO2010071692A2 (en) 2008-06-18 2010-06-24 Innovative Biotherapies, Inc. Methods for enhanced propagation of cells
WO2011076095A1 (en) 2009-12-21 2011-06-30 Tty Biopharm Company Limited Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
KR20130107203A (ko) 2010-05-04 2013-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. 섬유증의 검출 및 치료
WO2014074785A1 (en) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
EP2920319B1 (en) 2012-11-16 2020-02-19 Poseida Therapeutics, Inc. Site-specific enzymes and methods of use
CA2928411A1 (en) * 2013-10-22 2015-04-30 Bioincept, Llc Pif-transfected cells and methods of use
RU2553342C1 (ru) * 2014-04-18 2015-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) Способ лечения инфекционного перитонита в эксперименте
EP3929286A1 (en) 2015-06-17 2021-12-29 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
EP3341006A4 (en) 2015-08-28 2019-03-13 BioIncept LLC COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE
US11096987B2 (en) 2015-08-28 2021-08-24 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
WO2019126578A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755593A (en) * 1985-07-24 1988-07-05 Lauren Mark D Novel biomaterial of cross-linked peritoneal tissue
US5443954A (en) * 1987-10-30 1995-08-22 The United States Of America As Represented By The Department Of Health And Human Services Immortalized non-tumorigenic human bronchial epithelial cell lines
US4885238A (en) * 1987-10-30 1989-12-05 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human bronchial epitherial mesothelial cell lines
EP0456640A1 (en) * 1988-12-13 1991-11-21 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Genetically engineered endothelial cells and use thereof
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU625013B2 (en) * 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
DE4011100A1 (de) * 1990-01-18 1991-10-10 Jakob Dr Bodziony Ein extrakorporales oder ein implantierbares bio-artifizielles organ, welches verschiedene organfunktionen ersetzen oder unterstuetzen kann
DE4001319A1 (de) * 1990-01-18 1991-07-25 Jakob Dr Bodziony Ein implantierbares und biologisch aktive substanzen sezernierendes bioartifizielles organ
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
IE911115A1 (en) * 1990-04-10 1991-10-23 Canji Inc Gene therapy for cell proliferative diseases
DE4123629A1 (de) * 1990-08-06 1992-02-20 Jakob Dr Bodziony Ein implantierbares und biologisch aktive substanzen sezernierendes bio-artifizielles organ, das auf dem prinzip des druckgradients funktioniert
ES2080341T3 (es) * 1990-09-14 1996-02-01 Univ Johns Hopkins Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral.
WO1992006180A1 (en) * 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
EP0563239A4 (fr) * 1990-12-20 1994-10-12 Univ Pittsburgh Gene recepteur tronque d'interleukine-1 utilise pour le traitement de l'arthrite.
WO1992015676A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Somatic cell gene therapy
AU663725B2 (en) * 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents

Also Published As

Publication number Publication date
JP3466194B2 (ja) 2003-11-10
DE69426328D1 (de) 2000-12-28
AU7174194A (en) 1995-01-17
AU688342B2 (en) 1998-03-12
EP0703988B1 (en) 2000-11-22
ATE197719T1 (de) 2000-12-15
US6068837A (en) 2000-05-30
EP0703988A1 (en) 1996-04-03
CA2164424A1 (en) 1995-01-05
EP1024197A3 (en) 2005-11-23
JPH09501048A (ja) 1997-02-04
DE69426328T2 (de) 2002-05-29
EP1024197A2 (en) 2000-08-02
US5645829A (en) 1997-07-08
WO1995000654A1 (en) 1995-01-05

Similar Documents

Publication Publication Date Title
ES2152986T3 (es) Genoterapia de celulas mesoteliales.
ES2032221T3 (es) Procedimiento para la obtencion de un sistema terapeutico transdermal multicapa.
ES2091226T3 (es) Agentes citotoxicos que comprenden maytansinoides y su utilizacion terapeutica.
ES2068897T3 (es) Una sustancia biocompatible, tromborresistente que comprende hirudina, sus analogos o fragmentos, y metodos para producir la misma.
ES2121793T3 (es) Composiciones de uso local para la administracion transdermica de derivados profarmacos de morfina.
DE3875700D1 (de) Wirkstoff - monoklonale antikoerper - konjugate.
ES2176355T3 (es) Formulaciones de aerosol de peptidos y proteinas.
ES2059729T5 (es) Preparado farmaceutico de liberacion controlada y metodo para producir el mismo.
DE68910159D1 (de) Dosierform für Verabreichung in der Humanmedizin.
KR890000098A (ko) 세포 및 조직 수복제
ES2035259T3 (es) Compuesto absorbente.
ES2067743T3 (es) Dispositivo y metodo para liberar un farmaco iontoforeticamente.
DE3484779D1 (de) Pharmazeutische mittel.
MX9704550A (es) Formulaciones de medicamentos en aerosol.
ES2152990T3 (es) Principios activos y microparticulas que contienen gases.
AR092919A2 (es) Composicion farmaceutica liquida
DK59182A (da) Farmaceutiske midler med kontinuerlig frigoerelse
ES2045906T3 (es) Estructuras de liberacion gradual para goma de mascar.
AR241676A1 (es) Suministrador de agente beneficioso a un ambiente de uso.
AR074958A2 (es) Composicion farmaceutica liofilizada de anticuerpos monoclonales o policlonales y procedimiento para su produccion
CO4290295A1 (es) Medicamento en forma de comprimido con liberacion retardada de sustancia activa
ES2094539T3 (es) Preparacion farmaceutica y procedimiento para su preparacion.
ES8504140A1 (es) Procedimiento para la preparacion de nuevos bencimidazoles substituidos
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
ES2093699T3 (es) Metodo y composiciones para inhibir la angiogenesis.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 703988

Country of ref document: ES